SCHEMBL30694265

SCHEMBL30694265

CC(=O)OC1CCCc2ccc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CHRM4 P08173 5/20 0.41
DRD2 P14416 5/20 0.41
HTR7 P34969 5/20 0.41
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
ABHD6 Q9BV23 1/20 0.34
CYP19A1 P11511 5/20 0.33
SSTR4 P31391 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TBXAS1 P24557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10286040 1.00 HDAC1 (0.42) HDAC1HDAC8HDAC6CHRM4DRD2
SCHEMBL14885005 1.00 HDAC1 (0.42) HDAC1HDAC8HDAC6CHRM4DRD2
SCHEMBL3955281 0.92 CHRM4 (0.40) HDAC1HDAC8HDAC6CHRM4DRD2
SCHEMBL10286027 0.84 CHRM4 (0.39) CHRM4DRD2HTR7HTR2AHTR2C
SCHEMBL10286160 0.83 CHRM4 (0.39) CHRM4DRD2HTR7HTR2AHTR2C
SCHEMBL30484353 0.83 CHRM4 (0.39) CHRM4DRD2HTR7HTR2AHTR2C
SCHEMBL10286793 0.81 CHRM4 (0.38) CHRM4DRD2HTR7CYP19A1ALDH1A1
SCHEMBL14885003 0.79 CHRM4 (0.41) HDAC8HDAC6CHRM4DRD2HTR7
SCHEMBL10286028 0.79 CHRM4 (0.41) HDAC8HDAC6CHRM4DRD2HTR7
SCHEMBL4761653 0.78 HDAC1 (0.40) HDAC1HDAC8HDAC6HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536664-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BeiGene, Ltd. (KY) 2025-04-16 EP disclosed
CN-119403805-A Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2025-02-07 CN disclosed
WO-2023237049-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-12-14 WO disclosed